Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2022-11-22 Capital/Financing Update
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 17, 2022, reporting the entry into an underwriting agreement for a public offering of common stock by RAPT Therapeutics, Inc. It details the terms of the offering, the number of shares, pricing, and the closing date. The document includes exhibits such as the underwriting agreement and legal opinion. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and financing activity. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is about 4964 characters, which is sufficient to contain substantive information about the financing event rather than just an announcement or a brief notice.
2022-11-22 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to 424(b)(5) under a shelf registration statement. It details an offering of common stock, including the number of shares, pricing, underwriting discounts, and use of proceeds. It includes risk factors, legal matters, and other information typical of a securities offering document. This is a capital raising document related to financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering terms, confirming it is not merely an announcement or a brief notice.
2022-11-18 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to SEC Rule 424(b)(5) related to a common stock offering of $75 million by RAPT Therapeutics, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. The document references a registration statement and is clearly a capital raising disclosure. It is not a financial report, earnings release, or management discussion, but rather a financing update and offering document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2022-11-17 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically states that the company issued a press release announcing its financial results for the quarter and nine months ended September 30, 2022, and that the press release is furnished as an exhibit. The document itself does not contain the financial results but references the press release. The length is 3716 characters, which is relatively short and consistent with an announcement rather than a full earnings release. According to the rules, if a document is short and announces or furnishes a press release of financial results, it should be classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results. The document is not the full transcript or detailed report but the official announcement of results via press release. Therefore, the correct classification is Earnings Release (ER).
2022-11-10 English
PRIMARY DOCUMENT
Director's Dealing
2022-11-03 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.